Type 2 Diabetes and Dementia details the relationship between diabetes, dementia and the future of medicine and therapeutics. Chapters range from epidemiology, clinical features, neuroimaging biomarkers, neuropathology, macrostructural and molecular mechanisms, risk assessment and prevention strategies, and the application of therapeutics. The book reflects the translational aspects of the current science in the field, with an emphasis on the display of neuroimaging and neuropathology. It contains contributions from world experts, and is ideal for clinicians and researchers in the fields of neurology, neuroscience, geriatric medicine and endocrinology.
Dr. Srikanth is an Associate Professor in the Department of Medicine, School of Clinical Sciences at Monash Health at Monash University in Melbourne, Australia. He is also a Specialist Geriatrician in Neurosciences & Geriatric Medicine at Monash Health. He is the Head, Stroke and Ageing Research and Lead of the Vascular Brain Aging Division. Dr. Srikanth is an NHMRC Career Development & Heart Foundation Future Leader Fellow. His research focuses on the effects and mechanisms of brain aging in cohort studies, with particular reference to the interface between metabolic disease, cerebrovascular disease and neurodegeneration. Zoe Arvanitakis is a Professor of Neurology at the Rush Memory Clinic, Armour Academic Center in Chicago, IL USA
1. Introduction 2. Epidemiology of type 2 diabetes and dementia 3. Magnitude and trajectories of Type 2 diabetes mellitus (DM)-associated cognitive dysfunction 4. Brain Imaging in Diabetes 5. Cerebrospinal Fluid and Blood-Based Biomarkers in Alzheimer's Disease and Type 2 Diabetes Spectrum Disorders 6. Neuropathologic insights into diabetes 7. Diet, obesity, exercise, metabolism and brain 8. The role of insulin resistance and signalling in dementia 9. Advanced Glycation, Diabetes and Dementia 10. Neuroinflammation, Type 2 Diabetes and Dementia 11. The blood-brain barrier in diabetes mellitus 12. Pharmacological and non-pharmacological interventions for cognitive impairment and dementia related to type 2 diabetes and metabolic disturbances in aging